Aarti Drugs Limited (524348) Earnings Call Transcript
May 7, 2025
Earnings Call Speaker Segments
Good day, everyone, and welcome to the Q4 FY ’25 earnings conference call for Drugs Limited. Just a reminder that all participant lines are listen-only, and once the presentation wraps up, you’ll have a chance to ask questions. If you need help at any point during the call, please signal an operator by pressing star then zero on your touchtone phone. Please be aware that this conference is being recorded. I’ll now turn the call over to Mr Adish, COO and CFO of Drugs Limited. Thank you, and over to you, sir.
Thank you. Good morning, everyone. I'm delighted to welcome all of you to Limited's earnings conference call. We appreciate your time in joining us today as we discuss the financial and operational results for the 4th quarter and the full year that ended 31st March 2025. With me on this call are Mr Harshit, Joint Managing Director; Mr, Managing Director of Private Limited, along with our Investor Relations Advisor, SGA. We hope you've had a chance to go through our financial results and investor presentation, both of which have been posted on the stock exchanges and on our company website. In Q4 FY '25, revenues rose by 9% to INR679 crores, with EBITDA margins improving to 14%. Through the quarter, we saw robust global demand for API, which drove a 15.5% increase in volume, led mainly by exports; helped by better operating leverage and steady input cost, we delivered EBITDA margins of around 14.5% in the standalone business. That marks a strong improvement from the past few quarters, in which margins stayed in the 11% to 12% range. We expect our consolidated margin of 14% to improve further next year, with our new facilities operating in FY '26.
PAT came in at INR653 crores, up 33% year-on-year, with PAT margins of 9.2%. For the full-year FY ’25, it was a challenging year, beginning with muted global demand, elevated raw-material cost, which impacted overall performance. Greater-than-expected market volatility, particularly to the falling input prices, led to a 5% year-on-year revenue decline. Despite the challenges, the company improved cost-efficiency and operational discipline over the year, which helped maintain our EBITDA margins at 12.6% on annual basis. Margin performance improved significantly in second-half of FY ’25, driven by stabilization in input cost. For FY ’25, the decline in revenue from the API business of 4% is not indicative of structural weakness, but rather reflected a transient correction in global pricing and inventory cycles. Despite this, the company successfully maintained operational momentum and continued to focus on strategic execution across all segments. For the full-year, one of the most significant positives for the year was marked by the improvement in gross margins, which improved over 200 basis-points to 35.8%. This improvement is primarily attributed to the normalization of the of input cost during the second-half of fiscal year and following a period of inflationary pressure in raw-material procurement. Looking-forward, as mentioned earlier, we anticipate further improvement in gross margins driven by multiple factors.
We expect a rise in selling price realization as global API demand returns to normal, along with better capacity utilization and more opportunities for higher-value exports. I'd also like to point out two significant strategic moves that show how we're concentrating on regulatory compliance and sustainability. In the quarter, the company signed a shared subscription and shareholders agreement with Green Power Private Limited and Green Power 9 Private Limited. Under this agreement, the company will pick up 26.25% of equity shares and voting rights, plus compulsory mix convertible debentures, in Green Powered 9 Private Limited and an SPV that will build and run a 24.4 megawatt peak solar power plant. That plant will cover part of the company's power requirements in both Maharashtra and Gujarat, strengthening the commitment to renewable energy. The total investment committed comes to INR8.05 crores, to be put in in a phased manner. We're also glad to report that the company got a letter from USFDA on 14th February 2025, which has formally taken our API manufacturing facility at Karapur off import Alert 66 to 40. This lets us restart exports to the US market from that facility. The key APIs cleared for export include hydrochloride, titrate, hydrochloride, silicoxin and.
This represents a significant regulatory step forward for the company and reflects our steadfast dedication to compliance on a global scale and to upholding high-quality standards throughout our manufacturing operations. Next, we'll provide an update on the capital investment that is currently underway. The capex incurred during the full year of FY ’25 came to INR177 crores. Recently, in line with our long-term strategy of deepening backward integration and enhancing cost competitiveness, the company has made substantial progress on its greenfield project at Saika, Gujarat, dedicated to backward integration of our anti-diabetic product along with a few more intermediates has commenced trial production, which is expected to stabilize soon during the current quarter. This is anticipated to contribute meaningfully to the company’s profitability over a long period of time. This development is expected to meaningfully reduce our reliance on external raw materials, improve supply-chain reliability and drive incremental margin expansion through internal sourcing of key imports. The Tarapur greenfield project had certain initial operational challenges which have now been largely resolved, the company remains focused on a gradual production scale-up targeting over 700 tonnes per month-by the month of June 2025 and aiming to reach a cumulative capacity of approximately 1,500 tonnes per month-by the end of FY ’26. These initiatives are expected to reduce the cost along with the expansion in the profit margin and the top-line growth.
Geopolitical difficulties are still affecting the wider operating landscape, and the company keeps its attention on boosting profitability via rigorous expense management and effective supply-chain operations. Taken together, these efforts should reinforce how resilient the business's operations are and prepare it for growth that lasts over the long term. That said, we're ready to start the Q&A portion now. Thank you.
Many thanks. At this point we'll open things up for questions. To ask one, you can press star and one on your touchtone phone. Should you want to drop out of the queue, press star and two. We ask that participants use their handsets when posing a question. Ladies and gentlemen, we'll pause briefly while the queue is put together. Our first question comes from AM Lodha at Consultant. Please go ahead.
Hello there. Good morning, Mr Patil. Can you hear me, sir?
Yeah, yeah, go ahead, please.
Sir, I’ve got two questions. The first concerns exports, and the second concerns expansion. Let me start with the export question. According to your letter dated 14th February ’25, the US-FDA has taken the 6640 alert off, and from your presentation I gathered that 11% of exports go to the USA, North-America. So I just wanted to know about North-America, 11% of exports to North-America. I just wanted to know whether, after this import alert has been removed, the company can improve export performance from your Tarapur plant. Another export-related question: from the presentation I gathered that Pakistan is also among the top-10 countries. Recently the government of India has prohibited export to Pakistan, directly and indirectly. So what percentage of exports goes to Pakistan? Those are the two questions on the export side.
Alright. Alright. Yes. So to address your first question: yes, roughly 11% of our exports go to North America — though that figure covers three countries: Canada, the US, and Mexico as well. Now, with the USFDA clearance, sales — API sales into the US ought to rise, in principle. That said, there will be a gestation period of, say, 12 to 24 months, since every one of those projects has been reinitiated. A couple of clients are already active, and they too will launch their product using our API. Another point: this removes the stigma among European buyers. We hold very large potential for selling APIs into the European market, which had been held back because of this import alert issue. So the USFDA import alert clearance will definitely give us a lot of impetus when it comes to improving our regulated sales. That said, it will take — it will take some decision period, but improve it will, for sure. And it will be a high-margin business compared with our current ROW export sales. As for your question about Pakistan, it is a very — it's a relevant question today — today. So our exports to Pakistan stand at a little less than around 2.9% or so.
Absolutely, we're monitoring the developments in trade relations between India and Pakistan very closely. That will have an effect on that 2.9% of sales, and we'll try to redirect those to other countries, because as you can see, the market is quite large and at times we run short on production capacity. So we'll be in a position to shift that material to other nations. Sir. The second question concerns
Okay, so now I'll move on — please interrupt me, madam, if needed. The first question was only about exports. Now I'm asking my second question, which is about expansion, and after that I'll go back into the queue. No problem. Sir, my second question: you invested in a Saika plant. How much money has been invested in the Saika plant, and at full capacity utilization, how much can that plant generate? Similarly, we have invested in Tarapur, the greenfield plant — how much money has been invested, and how much sales can be generated over a period of two, three years at full capacity utilization? And out of that INR600 capex which we have undertaken in ’22 2022, how much money is still to be spent? That is the second picture.
Alright. So Saika and Tarapur, the two greenfield projects, each fall in a range of 180 to INR200 crores. That said, at present both are only at Phase-1. By Phase-1, I mean we are using just two-thirds of the land parcel. So one-third of that land will stay vacant, reserved for expansion later on and for additional production lines down the road. And the initial capex — greenfield CapEx always demands more capital, since we must handle plot development and all the ancillary work such as ETPs, utilities, and warehouses. So all of these common investments are already completed in the greenfield phase. As a result, for the second round of expansion, which will happen in this area at these locations, our asset turn is much higher. That said, the current — Phase-1, the Phase-1, Taika, we expect roughly INR200 crores, though I would note that close to 50% of it would go to our captive consumption. So that boosts our gross margin instead of boosting sales, while the Tarapur one carries a full-scale potential of roughly INR250 crores to INR300 crores, depending on API prices, which shift dynamically. So that range works out to around INR250 crore to INR300 crores per annum.
And regarding that INR600 of capex they announced back in 2022 — how much of it looks like it's still pending?
Yeah, most of that's finished. That said, the anti-diabetic expansion line we're planning at INR600 — that capex got deferred, and we'll likely take it up again in maybe a couple of years.
All right, sir, thank you. I'll get back in the queue, sir.
I appreciate it.
Thanks. Our next question comes from Rashmi Shetti at Dolat Capital. Go ahead, please.
Yeah, so Adish — just one line on deferred. For FY ’26, what’s the capex guidance, and then how should we be thinking about it in FY ’27?
Right. So this year we managed to spend roughly INR177-odd crores on capex. And what we foresee is that, going forward, on a consolidated basis, we're also looking to put money into registering oncology products within the formulation division, and we're planning as well for a probable additional block — a production line expansion that would serve the export market in formulation. Beyond that, for the standalone companies too, we can see capex of roughly around INR200 crores. Not all of it will be taken up in 2026 itself. So I'd say approximately INR150 crores to INR200 crores is the range of capex we might undertake in FY '26. Then again, a similar sort of amount probably in FY '27, once more newer products get identified? Okay. And how much of that 1500 would be dedicated to this line — that project, if we include it here, it should come to roughly around INR100-odd crores. Precisely, we don't have an estimate at this point, but roughly around INR100 crores or so.
Alright. And at this point, could you also tell us, for FY ’25 overall, what the rate variance was compared with FY ’24? And in the API segment, what was volume growth on an annualized basis for FY ’25 versus FY ’24?
All right. On volume — I don’t have the full-year figure available at the moment, but for the quarter, comparing year on year for the March quarter, what we observed is that domestic market volume growth was fairly steady. It was not all that large. Still, we recorded very high volume growth in the export market — close to late 20%. That is what drove overall volume growth of roughly 15% for this quarter.
And what about the
During the first half of fiscal year ’25, export demand proved quite soft. As we noted, election activity meant fewer tenders. So overall, demand for our export APIs was notably weak across that opening six months of FY ’25. That’s right.
What about the variance in rate?
Regarding rate variance, what we observed was roughly negative 4% to 5% versus a year earlier for the quarter, for the quarter.
Alright. And from one quarter to the next, it's holding steady.
On a quarter-over-quarter basis, things have nearly leveled off — nearly leveled off, with barely 1% or a million either way.
All right, so on the API segment, we did see a decline in FY ’25. So for FY ’26, with capacity utilization improving and demand coming back, what type of growth should we expect for the full year?
Looking ahead, we're certainly targeting growth in the double digits, and our hope is that essentially all of it comes from volume rather than from rate.
Alright.
The main driver there is going to be the new product-line expansion and the added capacity you've brought online — that's what should fuel the growth.
All right. And as for that rate variance, is it more or less expected to hold steady, or is it probably going to be in a declining phase only when compared with FY ’25?
Regarding fiscal year 2025, likely just the first 2 quarters — the first 2 quarters, meaning the first half — I'd say approximately a negative rate variance of about 3% to 4%.
Alright,
For the second half, we shouldn't see any negative rate variance.
Understood, noted.
That all comes down to whether raw-material prices begin climbing once more — if crude moves, then we won’t see that negative rate variance.
All right, my next question concerns specialty chemicals. We've also completed a brownfield expansion there and so on. Previously, we expected the sales potential to get to roughly over INR200 crores to INR250 crores within 2 years. So where do we stand at present? We've achieved about INR130 crores this year. So over the coming 2 years, will that figure be reachable, or do you think there are certain challenges there?
So we ought to be able to get there. What occurred in FY ’25 is that midway through the year, we made a decision — we were producing one specific chlorocel furnishing product using match manufacturing mode. We had moved to a newer process. Yet despite the quality parameters lining up, the performance — in the performance test, the user test, as you call it — there were some problems in the final application of the product. That is therefore why we switched back to the batch manufacturing process. As a matter of fact, we were incurring considerable losses under the new process, and those were reversed in the — midway through FY ’25, which also drove the margin improvement in the second half of FY ’25. So — but at this point we have moved into batch manufacturing, we have already scaled up to 100, and in this — by the June quarter, we will scale up to 200 tons per month. So it is on track. So we will be improving this segment going forward. And what we believe is that given the ongoing tariff situation between the US and China, this is a line where we might have some — we might gain some benefit as far as exports to the US are concerned.
That's an area we'd also be interested in exploring.
Understood. Finally, regarding margins — any guidance, we’ve already hit 13.8% this quarter. So in FY ’26, will we be able to hold that 13.8%, 14%, and then expand further in FY ’27, or does this quarter look more like an aberration that gained from several factors, meaning we’d likely land in the 12% to 13% range in FY ’26?
All right. So nothing of that specific kind came up during this quarter—it was driven entirely by solid demand and volume growth on the API side. On the API side, taking the standalone business, API plus and plus intern, we managed to hit 14.5% EBITDA margins. So our hope is that in the standalone company we'll hold that at least around 14%, somewhere between 14% and 15% we'll try to keep it. And as our acid plant scales up and the losses there come down, it should be relatively—you know, I'd say—easy to keep an EBITDA margin of 14% to 15% at the standalone level, and for—and for the formulation level, I will—Visha will shed some more light on that. Could you explain the margins on the formulation front? Yeah, sure. So on the formulation side, that side as well, in FY '25, we saw a sales dip because fewer drop production volumes were available, since we were carrying out some brownfield expansions and also ramping up regulatory audits. But in the current financial year, as we expect higher volumes and an increase in sales of about mid 20% levels, with that, our EBITDA level should also land in the range of 14% to 15% in chemicals as well.
At the consolidated level, we can assume 14% in FY ’26, I guess, for consolidating both segments. And we’ll try to achieve that.
All right. And as you said when discussing formulation, you're aiming for roughly 20% growth. Did I hear that correctly?
Yeah, yeah. So we're aiming for roughly 20% to 25% revenue growth in formulation.
Alright. I’ve got additional questions. I’ll rejoin the queue. Thanks.
Appreciate it.
Thanks. Our next question comes from Nitesh Dath at Capital. Go ahead.
Hello, sir, and thank you for the chance to ask. My question concerns the trade war that is currently going on between the US and China. I just wanted to get a sense of what sort of benefits it could deliver for us, in terms of higher volumes as well as improved realization for APIs? And have we already begun — started to observe any of those trends when it comes to rising prices, or that you can pass along to customers.
Honestly, the situation has been quite unpredictable, since even the US administration keeps shifting policy by striking newer and newer agreements. So at this moment, where things will end up is really unclear. Still, our overall view is this: if goods from China carry a higher tariff than those from India — say, just 10% — then that hands us a clear 10% edge on pricing for what we sell. That makes us 10% more competitive, and honestly, for Indian manufacturers that is a fairly large margin. That said, what we have noticed is that in most old-age molecules, the API goes to USFDA-approved formulation plants located outside the USA. So tariffs would hit the formulations rather than the API itself. Because of that, for API makers there really won't be much impact, frankly. In the chemical lines of business, though — chem products, perhaps some intermediates — where those go straight from China to the US, there we could see some gain in competitiveness and pick up additional market-share. So on that last point, are you referring to intermediates, KSM, and so on?
And if that happens, those could also end up being provided to, say, API makers outside the US, who would then supply them to formulation production facilities outside the US. What I'm referring to is the customers located within the US itself.
All right. Understood. Appreciate it. That was the sole thing I wanted to ask.
Thanks. Our following question comes from Vanil Desai at Turtle Capital. Go ahead.
Hi there, yes. Can you hear me okay?
Yes. Yeah.
Hi. So my question for you, Adish, is this: I believe on the last call, and on earlier ones as well, we guided to volume growth of 15% plus in FY ’26 and negative rate variance of 4%, 5% in the first half, given the higher base in the first half of FY ’25. So the question here is that this quarter we've delivered 15% volume growth, and we're scaling up both at Saika and Tarapur going forward. So should we assume that from the next quarter onward, throughout FY ’26, we'll keep growing off the Q4 base — is that the right way to look at it?
Yeah, ideally, Q2 ought to be even simpler for us, since by then both facilities should, in theory, be running at full tilt. So Q2 will be easier. Q1 — Q1, honestly, should also gain from this, because although half of Q1 has already passed — today we're on 7 May — the second half of Q1 will certainly see the advantage of that expanded output from the greenfield projects?
All right, so my question is this: should we treat Q4 as the base for API sales, and then keep growing from there quarter after quarter as we ramp up?
Right. The initial goal would be to keep those volumes up, at least as far as our usual API markets go. Plus, bringing in additional production lines and the new products themselves is going to provide extra momentum for growth — growth across the whole company.
Understood. Understood. The second question concerns gross margin. Our gross margins haven't really widened—perhaps roughly flat, or a touch lower quarter over quarter. So, as you know, it sits at about 35-odd percent. So how should we think about the gross margin path as we head into FY ’26, given all the backward integration and the improved product mix coming through.
Regarding the standalone business, we definitely experienced a fairly significant quarter-over-quarter decline in gross margin, but the main reason for that is annual discounts from three vendors that were recorded in the December quarter. So if I take that out, gross margins are more or less sustained. There is definitely a gap of about 0.5 crores, though that too hinges on product mix and similar factors. So what we're seeing is that it has more or less stabilized. And going forward, there would be two ways to raise gross margin. The first is on the sales side, which means boosting regulated sales. And on the input side, it would be backward integration, which is currently underway. So both of these factors will also help us further improve gross margins.
There's one point, Adish, that I just can't reconcile: we expect gross margin to get better next year. It gets better, and sales volume will — again, capacity utilization should rise, volume should increase, so operating leverage comes through. So in an ideal scenario, in FY ’26 our margin ought to be stronger than the level we closed FY ’25 Q4 FY ’25 at. Isn't that the correct way to see it?
Are you referring to the annual figure—what we achieved on margin—or just Q4?
No, not Q4 either — that’s what I’m saying.
On the annual figure, it's roughly 12%, 12% or thereabouts, and we fully expect that to get better by a percentage point or so — that's our anticipation. So we're aiming for something like 14% to 15%, and that's going to serve as our internal goal for EBITDA margins on a consolidated basis.
Understood, understood. Yeah. Thanks. I've got nothing further to add. Thank you.
Thanks. Our following question comes from Aman Goyal at Axis Capital Securities. Go ahead.
Good morning, sir. Congratulations on a great set of numbers. Sir, my first question relates to the revenue guidance. Could you guide the revenue for FY ’26 and ’27? Yeah. So frankly speaking, we are just taking into account that there might be some 3%, 4% negative rate variance in the first half of FY ’26; we still are optimistic about achieving a double-digit growth as far as revenues are concerned on a CAGR basis for the next two years. So at least. I mean, the thing is initially — our initial target would be to cross 3,000 crores on an immediate basis, and then from there we will try to reach 3.5 thousands; that is purely based on volumes, and we are not considering any rate improvement in that. Okay. So sir, basically this growth will be majorly coming from the API, right? It will come from API as well as it will come from formulations as well. Okay, sir. And the EBITDA margin guidance, if you could — 14% to 15%, right?
The guidance we're giving you is stable at 14% to 15%.
Alright, sir. Thanks. Thanks. That's everything from me.
Thanks. Thanks a lot. Thanks. Our following question comes from Ankit Gupta at Bamboo Capital, who is on the line. Go ahead, please.
Thanks for the chance to speak, and congratulations on a solid set of numbers. So my first question was about something, Abesh — you mentioned that INR622 crore of debt we’re carrying on a standalone basis, and that over the coming few quarters we’ll try to build on that, because Q4 is typically our strongest quarter, which historically we see as relatively high and among our best. Great. So from that, please.
Right, so Q4 is definitely one of the strongest, and Q2 is also pretty solid. So our first goal going forward would be to hold onto that base — maybe for the existing products and the existing line there could be a small dip here or there, but then the new products will come in, and those will also add a lot of growth overall.
Yeah, yeah, yeah. Okay. And I was just going over the figures. Looking at next year, we anticipate solid double-digit volume growth in our existing business. Our new plants will come online, and hopefully specialty Chemicals will ramp up as well. For Formulations, we're saying 20% to 25% growth. So at a consolidated level, do you think we can target at least 20% revenue growth next year?
No, actually the way things stand right now, it's roughly 10%, 12%, so growth will mostly land in that 10% to 15% kind of range — 10% to 15% on an overall basis.
So overall, you're looking at growth in the 10% to 15% range, even with new products coming in and the expansions coming in as well.
Yes.
Right, got it. Now, regarding your second question about margins — you mentioned that hopefully we should begin to see some improvement in gross margins as well, and with volume growth and revenue growth coming through, do you think there could be some operating leverage benefit that flows through next year, and that our margins could be higher than 14% 15%?
Right. So on gross contribution, we don’t anticipate much change going forward, apart from two things — regulated sales and backward integration — and both of those will play out over the due course of time. So that will — it will take us a little longer. Backward integration will come through much faster — within two quarters itself — but the regulated sales piece is a longer proposition. As for manufacturing — the other expenses, which are — which play a big role there, in power and fuel, we envisage being able to gain roughly 0.5% benefit in EBITDA margins from improvement in power and fuel, because we will be going in for renewable electrical units from a solar power plant that will drastically cut our power cost. The full — so full, and plus we are also going in — we have already gone for boilers. So we will be producing some amount of electricity, which will be captively consumed. So all put together, overall — on a full-year basis, the potential is somewhere between INR25 to INR30 crores of sales in power and fuel. However, for FY ’26, we feel around 10 crore to 15 CR — of benefit might come in this year itself.
And starting next year, that figure ought to land somewhere in the INR25 crores to INR30 crores range.
Right. Right, right. And the final question concerned your comment that on an immediate basis, we won’t hit revenue of roughly INR3,000 crore. So FY ’27 is the year we can look at if we assume that at least, you know, we should be the — just will aim to — yeah, we were pointed. FY ’26 appears somewhat hard to achieve, is what you were saying, INR3,000 crores of revenue. FY ’27. Okay, okay. Thank you very much.
Thanks. Our following question comes from Bhumika Jain at Advisory. Go ahead.
Can you hear me? Thanks. My question was about the products you said are in development, in the pipeline. Could you explain which ones you plan to launch in FY ’26, or in the first quarter of FY ’26? Yes. So which are the main products where you expect our new volumes to come from?
First is the product side. We also expect volume growth there, since they've raised output, and on top of that we anticipate a volume expansion because we've lifted production from roughly 245 to 330 tonnes per month. Then come the new products — salicylic acid, which we launched last year, though its meaningful contribution will only arrive this year. Beyond that, two additional products sit in methalamines, along with TMA, which we'll sell externally. DNA would be consumed captively. So as for any formulations — Visha, could you mention a few of the oncology products? Yes, so within formulations, we anticipate a handful of approvals for diabetic and cardiac products during Q1 and Q2 of FY '26.
Also with the DPV4 inhibitors, plus a few of those anti-cognant drugs, those are products we'd be launching. Then during the later half of the financial year, approvals should come through for at least two oncology drugs, so our plan is to launch those too by end-of-the financial year in regulated markets.
Alright, alright, sir. T
Thank you, Hank. Our next question comes from the line at Dolat Capital. Go ahead, please.
Thanks again for the chance to follow up. Regarding working capital, you can see that receivables days, inventory days, and creditor days have all risen. So could you shed some light on that, and will those stay at the same level over the next — for the next two years, all right. Inventory days, in fact, have gotten better in that respect.
Debtors do look inflated, though. The primary driver is the bump in sales during the last quarter — our data cycle, as you know, runs about 90 days typically. So when we sell more in the most recent quarter, and you base it on revenue from the first four quarters, the figure appears higher. However, if Q4 is multiplied by four and treated as annualized sales, then it comes out in line.
Right. And if you're modeling next year, it would stay at roughly these same levels.
If you can keep sales at this level, that works out to roughly INR624 standalone plus 378 each quarter. Should that pace continue, the figure stays where it is.
Right, one more thing about the gliptins — what's the latest there? Before, our focus was on ramping things up, increasing exports, and becoming more India-centric. So how are things going in that area — are we managing to lift sales or not?
No, we can't fully capture the sales from those teams just yet. The anti-rabetic growth you're seeing in our figures is coming from the 4 million. — we're selling into local markets, and we're in the process of making DMF. We're continuing to improve the cost and the process for Vilda meeting, because with a better process we should be able to move quickly and take the meeting market in exports, since pricing on those products has corrected quite a bit. So we have to be very cost-competitive to win that market.
All right. And finally, on that point — right now, as far as I understand, we're only selling in India plus the other emerging markets. So for that specific molecule, do we plan to go after regulated markets, meaning the US? And also, what's the latest regarding European markets?
Yes. So, within Europe, we hold approval and also have a CEP for the product. That said, European sales are still fairly muted, but there are several other semi-regulated markets around the world. We have only recently entered those markets, and volumes are picking up there, which is helping our overall numbers. So the next objective is Europe, since we already have the acquial at the plant level, and after that we aim to get our plant USFD approved. Our initial goal was to clear the import alert for the Karapur facility, which we accomplished this year, and that gives us a lot of confidence to file for the US payment. We are already working on the US payment. So very soon we will be filing the US payments and will try to trigger the USFD audit for the phone facility.
All right, all right, understood. Thanks. That's all I have to say.
Thanks. We’ll take the next question from Sanika at Sapphire Capital. Go ahead.
Hello, sir — is my voice coming through?
Right.
Hi there. Yeah. So during one of the interviews we did, we mentioned that by FY ’27 we’re aiming for INR4,000 crores in revenue. Is that still on track?
No, actually our goal was INR4,000 crores. The one issue is that, owing to price variation, we've made a revision to that goal. So as things stand, on a pessimistic level, we're hoping to first get to INR3,000 crores plus by FY ’27. And starting from there we'll try to do more and then try to get to INR3,500 crores.
Alright, alright. Alright. Alright. Thanks, sir — thank you.
Since nobody has any more questions, at this point I'd like to pass the conference back to management so they can offer their closing remarks.
Thank you all for being here today on this earnings call. We're grateful for the interest you've shown in Limited. Should you have any additional questions, please reach out to H.J., our Investor Relations Advisor, or to us directly. Thank you.
Thanks. Good to talk with you.
That brings this conference to a close on behalf of RT Drugs Limited. We appreciate you being with us, and at this point you can go ahead and disconnect your lines. Thank you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Aarti Drugs Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Aarti Drugs Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.